- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced the first commercial product launch based on its Priostar(R) dendrimer technology.
The product, a research reagent kit called NanoJuiceTM Transfection Kit for transporting DNA into cells, was developed under a license and supply agreement established in February 2007 between Starpharma's wholly owned US subsidiary Dendritic Nanotechnologies (DNT) and EMD Chemicals Inc., an affiliate of Merck KGaA, Darmstadt, Germany.
Under the commercial agreement, Starpharma retains full rights to all in vivo aspects of transfecting DNA and other nucleic acids such as siRNA with products based on Priostar(R) technology. Starpharma supplies the Priostar(R) dendrimers and will receive royalties from the sale of the transfection kits.
The NanoJuiceTM Transfection Kit launched by EMD Chemicals will be marketed to researchers as an improved product for optimal transfection efficiencies, low toxicity to cells and flexibility in the conditions of transfection.
In addition, the reagent is suitable for use with all types of cell growth media and does not require that the medium be changed after addition, thereby affording researchers substantial savings in time and money.
The transfection reagent in the kit is based on Starpharma's Priostar(R) dendrimers, highly branched spherical molecules with a high concentration of active groups on the surface that bind to DNA and are taken up by cells. It is the only reagent available that has been optimized for different cell lines through the use of different sizes of dendrimer.
The kit was designed to achieve efficient transfection of mammalian cells, especially those derived directly from tissues (so-called 'primary' cells), as well as the cell lines that are traditionally difficult to transfect.
The kit consists of Priostar(R) dendrimers mixed with microscopic lipid-based spheres that carry multiple positively charged groups.
DNT expects EMD to launch a related siRNA transfection reagent kit later in 2008.
About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
For more information, please click here
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Abalonyx launches Reduced Graphene Oxide Product: Abalonyx has successfully scaled up production of thermally reduced graphene oxide (rGO) in its Tofte, Norway, production facility. This product is now offered to customers in Kg-quantities May 10th, 2016
New Generation of Graphene Reinforced Carbon Fibre Prepreg Products March 14th, 2016
New Generation of Graphene Reinforced Carbon Fibre Prepreg Products March 10th, 2016